LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Dr Jack Regan notes that the firm is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on human urine samples. Dr Regan says ASL has the ability to bring LexaGene's diagnostic in-house, validate it, and begin using it for clinical diagnostic.
Full interview: LexaGene teams up with Assurance Scientific to beta test its diagnostic in humans
Quick facts: LexaGene Holdings Inc.
Price: 0.85 CAD
Market Cap: $96.66 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE